25 reports of this reaction
4.3% of all CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE reports
#3 most reported adverse reaction
ACNE is the #3 most commonly reported adverse reaction for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, manufactured by Bausch Health US, LLC. There are 25 FDA adverse event reports linking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE to ACNE. This represents approximately 4.3% of all 579 adverse event reports for this drug.
Patients taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE who experience acne should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACNE is moderately reported among CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE users, representing a notable but not dominant share of adverse events.
In addition to acne, the following adverse reactions have been reported for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE:
The following drugs have also been linked to acne in FDA adverse event reports:
ACNE has been reported as an adverse event in 25 FDA reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACNE accounts for approximately 4.3% of all adverse event reports for CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, making it one of the most commonly reported side effect.
If you experience acne while taking CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.